1. Home
  2. PNRG vs SABS Comparison

PNRG vs SABS Comparison

Compare PNRG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PNRG

PrimeEnergy Resources Corporation

HOLD

Current Price

$211.50

Market Cap

315.5M

Sector

Energy

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

SELL

Current Price

$2.89

Market Cap

344.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PNRG
SABS
Founded
1973
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
315.5M
344.8M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
PNRG
SABS
Price
$211.50
$2.89
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $11.64
AVG Volume (30 Days)
58.5K
★ 585.9K
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 78.53
EPS
★ 4.57
N/A
Revenue
★ $189,052,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$46.09
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$126.40
$2.10
52 Week High
$278.90
$5.15

Technical Indicators

Market Signals
Indicator
PNRG
SABS
Relative Strength Index (RSI) 56.07 26.55
Support Level $205.98 N/A
Resistance Level $225.59 $3.99
Average True Range (ATR) 7.00 0.19
MACD 0.31 -0.04
Stochastic Oscillator 88.05 17.39

Price Performance

Historical Comparison
PNRG
SABS

About PNRG PrimeEnergy Resources Corporation

PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: